Literature DB >> 833760

Clofibrate and clofibric acid: comparison of the metabolic disposition in rats and dogs.

M N Cayen, E S Ferdinandi, E Greselin, W T Robinson, D Dvornik.   

Abstract

In rats, equimolar oral doses of [14C]clofibrate and [14c]clofibric acid produced essentially the same profiles of blood levels, tissue distribution and excretion of radioactivity. Both compounds were completely absorbed, and all radioactivity found in the serum was due to clofibric acid (CPIB). Tissues contained readily detectable radioactivity levels, but the concentration was generally lower than in serum. A large proportion of CPIB in liver, heart, kidney, fat and muscle was associated with intracellular space. In rat urine, CPIB was present both free and conjugated with glucuronic acid. Approximately 97% of the serum CPIB was not conjugated. Identical decreases in serum lipids and hepatic cholesterol synthesis were observed in rats treated for 1 week with either compound. In dogs, the serum contained 40% more radioactivity after [14C]clofibric acid than after an equimolar oral dose of [14C]clofibrate; approximately 88% of the serum radioactivity was due to CPIB. Some biliary excretion was detected. The extent of binding to serum protein varied with concentration of CPIB and with the species; the affinity was in the order man greater than dog greater than rat. The results demonstrate that clofibric acid and clofibrate are metabolically and pharmacologically equivalent in rats, but not in dogs. The data are in accordance with the view that the pharmacological activity of clofibrate is due to clofibric acid.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 833760

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Modulation of the gating of CIC-1 by S-(-) 2-(4-chlorophenoxy) propionic acid.

Authors:  E C Aromataris; D S Astill; G Y Rychkov; S H Bryant; A H Bretag; M L Roberts
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

2.  Sex-related difference in the inductions by perfluoro-octanoic acid of peroxisomal beta-oxidation, microsomal 1-acylglycerophosphocholine acyltransferase and cytosolic long-chain acyl-CoA hydrolase in rat liver.

Authors:  Y Kawashima; N Uy-Yu; H Kozuka
Journal:  Biochem J       Date:  1989-07-15       Impact factor: 3.857

3.  Species variation in the taurine conjugation of clofibric acid [proceedings].

Authors:  J Caldwell; T S Emudianughe; R L Smith
Journal:  Br J Pharmacol       Date:  1979-07       Impact factor: 8.739

4.  Bile formation and biliary lipid composition under the influence of clofibrate and phenobarbital pretreatment in the rat.

Authors:  K Kutz; A Schulte; C Just; H Lindstaedt; B Reiter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-08       Impact factor: 3.000

5.  New metabolites of fenofibrate in Sprague-Dawley rats by UPLC-ESI-QTOF-MS-based metabolomics coupled with LC-MS/MS.

Authors:  A Liu; Y Chen; Z Yang; Y Feng; W Rui; W Luo; Y Liu; F J Gonzalez; R Dai
Journal:  Xenobiotica       Date:  2009-04       Impact factor: 1.908

6.  Liver gene expression profiles of rats treated with clofibric acid: comparison of whole liver and laser capture microdissected liver.

Authors:  Cécile Michel; Chantal Desdouets; Béatrice Sacre-Salem; Jean-Charles Gautier; Ruth Roberts; Eric Boitier
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

7.  Genetic loss or pharmacological blockade of testes-expressed taste genes causes male sterility.

Authors:  Bedrich Mosinger; Kevin M Redding; M Rockwell Parker; Valeriya Yevshayeva; Karen K Yee; Katerina Dyomina; Yan Li; Robert F Margolskee
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

8.  Hypolipidemic effects of clofibrate and selected chroman analogs in fasted rats: II. High sucrose-fed animals.

Authors:  A Mukhopadhyay; S T Patel; M O'Brien; S S Kokrady; H A Newman; D T Witiak; R R Lanese; J C Rice; D R Feller
Journal:  Lipids       Date:  1983-01       Impact factor: 1.880

9.  Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics.

Authors:  Aiming Liu; Andrew D Patterson; Zongtao Yang; Xinying Zhang; Wei Liu; Fayang Qiu; He Sun; Kristopher W Krausz; Jeffrey R Idle; Frank J Gonzalez; Renke Dai
Journal:  Drug Metab Dispos       Date:  2009-02-27       Impact factor: 3.922

10.  Urinary glucuronide excretion of fenofibric and clofibric acid glucuronides in man. Is it polymorphic?

Authors:  H F Liu; M Vincent-Viry; M M Galteau; R Guéguen; J Magdalou; A Nicolas; P Leroy; G Siest
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.